HKG: 1801

Explore the latest insights on HKG: 1801 and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of HKG: 1801’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves Viatris's RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label
CompanyDrug

FDA Approves Viatris’s RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label

Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is already…

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Innovent Biologics’ H1 2022 Revenue Rises 15.3% on Drug Sales Growth

CompanyDrug

Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363

CompanyDrug

IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China

CompanyDrug

Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy

CompanyDrug

Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial

CompanyDrug

Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME

CompanyDeals

Innovent Biologics and Sanofi Announce License Deal for Drug Development in China

Company

Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved

Show More